Search results

The Innovative Licensing and Access Pathway (ILAP) is a unique initiative which works with medicine developers early on to help get new medicines to patients faster.

Tools for building or evaluating a medtech evidence base with NICE

Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.

Learn from NICE International, part of the UK's National Institute for Health and Care Excellence, about how to improve your nation's health and wellbeing

We assess the value of digital health technologies that offer the greatest potential to improve health and wellbeing.

Access free webinars and paid-for masterclasses.

NICE's technology appraisal and highly specialised technologies guidance manual

Our experts can offer advice and support in contextualising our guidelines, or helping you adapt our content to your country or local context.

Resources to help with NHS access, system engagement and understanding the therapeutic landscape.

We provide an advisory service for international health organisations, ministries and government agencies whose task is to improve evidence-based decision making in health and social care.

NICE's partners

NICE's past research and projects

Home What NICE does Life sciences: how to get your product to market NICE Advice service {"@context":"http://schema.org","@type":"BreadcrumbList"

The EQ-5D is a short questionnaire used to understand how a person’s health affects their quality of life. It is used in health research and to help inform decisions about healthcare treatments.

NICE has implemented new measures to evaluate the cost-effectiveness of medicines, following a policy change that aims to give patients improved access to treatments. This follows the government’s decision to increase the thresholds that NICE can use in technology appraisals to £25,000 to £35,000 per quality-adjusted life year gained.